Doctors can prescribe GLP-1 drugs to 12-year-olds with adolescent obesity

A 12-year-old walking into a pediatrician’s office today can walk out with a prescription for the same class of drug that has reshaped adult weight loss culture, emptied gym memberships in favor of injections, and turned Ozempic into a household name.

It has been true since December 2022, when the FDA expanded approval of semaglutide, sold as Wegovy, to adolescents aged 12 and older with obesity. Liraglutide, sold as Saxenda, received the same green light two years earlier. What has changed is not the rule but the behavior around it, and that shift is worth understanding.

The rule is 3 years old. The behavior shift is brand new

The legal pathway for prescribing GLP-1 drugs to adolescents has existed for years, so why does the topic keep resurfacing in parenting forums, school pickup lines, and news coverage? The answer is volume.

A 2024 study found a 504% increase among boys and a 588% increase among girls in GLP-1 prescriptions dispensed to adolescents between 2020 and 2023, and that climb has not leveled off. Prescriptions for semaglutide and liraglutide among young people rose 700% between 2022 and 2024. Numbers like that no longer describe a niche medical decision. They describe a behavioral shift moving through pediatric care at a pace most parents have not had time to absorb.

The trigger point was clinical guidance, not just FDA approval. In January 2023, the American Academy of Pediatrics released guidelines recommending that pediatricians offer obesity medications to patients 12 and older whose body mass index sits at or above the 95th percentile for their age and sex.

That recommendation reversed decades of a watch-and-wait approach to childhood obesity, one built on the assumption that weight issues in children should be managed primarily through diet and behavior change, with medication reserved as a last resort. The AAP guideline treated that approach as outdated and arguably harmful, given how often it left adolescents with severe obesity untreated until adulthood.

Less than 1.4 percent of eligible teens are on these drugs

Despite the percentage increases that make headlines, the raw numbers remain small. A CDC-affiliated study found that even after the 2023 guideline drove a roughly 300% increase in prescribing compared with 2020, only 0.5% of adolescents with obesity were prescribed an obesity medication in 2023.

A more recent national dataset tracking through mid-2025 found that the prevalence had climbed further but remained under 1.4% of the eligible population. Among more than two million adolescents with obesity, just 19,097 received at least one GLP-1 prescription, and 87.4% of those adolescents had severe obesity, not the milder end of the BMI range some parents fear is being swept into casual prescribing.

That detail matters because it complicates the narrative of GLP-1 drugs as a shortcut handed out broadly to anxious parents and image-conscious teens. A majority of prescriptions, 83%, went to adolescents with severe obesity, classified as class 2 or class 3, not the lower threshold that simply crosses into the 95th percentile.

Indian pediatric guidance, citing the same FDA framework, restricts use specifically to children with class 3 obesity tied to life-threatening comorbidities and a BMI of 40 or above. The drugs are reaching the adolescents the guidelines were written for, even as the broader cultural conversation treats the headline figure as evidence of overreach.

Gender and age patterns inside the data tell their own story. Girls receive these prescriptions at roughly twice the rate of boys, and adolescents aged 15 to 17 are more than twice as likely to be prescribed an obesity medication as those aged 12 to 14.

Whether that reflects differences in how obesity affects boys and girls physically, differences in how parents and clinicians perceive urgency by gender, or both, is a question the data cannot yet answer on its own.

The maturity bar for a 12-year-old looks nothing like the one for adults

The clinical case for offering these drugs earlier is built on outcomes. Studies show GLP-1 medications help teens lose between 5% and 16% of body weight when combined with lifestyle changes, a range that for adolescents with severe obesity and weight-related health complications can mean the difference between manageable and worsening disease trajectories.

The hesitation comes from a different place: time. Use in children will likely stay slow because doctors are still learning about the long-term effects on growing bodies. That caution is echoed by pediatric centers advising families directly. Lurie Children’s Hospital tells parents that while short- to medium-term evidence shows the medications are safe, there is no decades-long data on what happens to children who take GLP-1 drugs throughout childhood and into adulthood, a gap that matters more for a 12-year-old with 70 years ahead of them than for a 55-year-old patient.

Eligibility criteria for newer pediatric studies make the maturity question explicit rather than implicit. Clinical trial protocols now require that adolescent participants demonstrate sufficient maturity, psychological stability, and cognitive capacity to understand what being on medical therapy means and to follow the behavioral changes it requires.

That is a strikingly different bar from the one applied to adult patients, and it reflects how differently the medical establishment treats the decision when the patient is a child rather than an adult making the choice for themselves.

The real frontier is the kids under 12

Parents encountering this news for the first time are often reacting to a decision that clinicians made years ago, based on data showing that untreated severe obesity in childhood carries its own long-term risks.

The frontier worth watching now is not whether 12-year-olds can access these drugs, since that question was settled in 2022. It is a question of whether the same logic will eventually extend to children younger than 12, with pediatric trials already quietly underway despite the same long-term safety questions. That is the conversation parents should be preparing for next.

Disclaimer – This list is solely the author’s opinion based on research and publicly available information. It is not intended to be professional advice.

Like our content? Be sure to follow us.